Nitin Kumar K. Swarnakar, Ph.D. (he/him/his)

NA Applications Lab Manager
BASF Corporation

Nitin K Swarnakar, North America Application Lab Manager at BASF Corporation, leads pharmaceutical solution development focusing on oral and parenteral drug products. With over 16 years of industry experience, he has guided the creation of sustained, controlled, and enhanced bioavailability formulations. Before BASF, he managed oral and parenteral formulations at TesoRx Pharma and contributed to generic product development at Ajanta and Macleods Pharma.

Nitin has co-invented 10 patents and authored over 35 publications, streamlining continuous manufacturing and improving difficult-to-deliver drugs for global markets.

Poster(s):

• (W0930-02-11) Impact of Direct Vs Indirect Simulation on Material Strength and Deformation Parameters
  Wednesday, November 12, 2025

  9:30 AM - 10:30 AM CT

• (T0930-09-60) Poloxamers in Continuous Melt Granulation: Dual Role as a Binder and a Solubilizer
  Tuesday, November 11, 2025

  9:30 AM - 10:30 AM CT

• (M1030-02-08) Evaluation of Tableting Characteristics of Copovidone-Based ASDs Using CTC and Heckle Analysis
  Monday, November 10, 2025

  10:30 AM - 11:30 AM CT

• (W1130-06-37) Data-Driven Formulation of Solid Oral Dosage Forms: Computational Modeling to Experimental Validation Using ZoomLab^TM
  Wednesday, November 12, 2025

  11:30 AM - 12:30 PM CT

• (M1130-06-39) Biosustane as a Novel Oral Excipient for Solid Dosage Forms – Formulation Development, Characterization, and IVIVC Prediction
  Monday, November 10, 2025

  11:30 AM - 12:30 PM CT

• (T1130-07-46) ZoomLab^®-Enabled Development of Directly Compressible Solid Dosage Forms with a Novel Co-processed Excipient
  Tuesday, November 11, 2025

  11:30 AM - 12:30 PM CT

• (T1230-06-38) Kolliphor® P407-CPBA Functionalized PLGA Nanoparticles for Co-Delivery of Sorafenib and Venetoclax: A Synergistic Strategy Targeting Ferroptosis and Apoptosis in Breast Cancer
  Tuesday, November 11, 2025

  12:30 PM - 1:30 PM CT

• (W1230-08-54) Overcoming Flow, Blend Uniformity and Direct Compression Tabletability Challenges in Micronized APIs Through Use of Multi-Functional Excipients
  Wednesday, November 12, 2025

  12:30 PM - 1:30 PM CT

• (T1230-09-57) Application of X-Ray CT Scan and Material Profiling to Evaluate Tableting Performance of Kollitab™ DC 87 L
  Tuesday, November 11, 2025

  12:30 PM - 1:30 PM CT

• (M1330-08-54) Critical Insights into High Drug Load Amorphous Formulations: Challenges and Advanced Techniques
  Monday, November 10, 2025

  1:30 PM - 2:30 PM CT

• (T1330-09-57) Efficient Manufacturing of Omeprazole Modified-Release Pellets Using Talc-Free Aqueous Coating System
  Tuesday, November 11, 2025

  1:30 PM - 2:30 PM CT

• (M1330-09-58) Berberine Hydrochloride Amorphous Solid Dispersion via Hot-Melt Extrusion for Taste Masking and Bioavailability Enhancement
  Monday, November 10, 2025

  1:30 PM - 2:30 PM CT

• (T1430-09-56) Impact of Dosage Form on Drug Release from Danazol-ASD at LoC: A Comparative Study
  Tuesday, November 11, 2025

  2:30 PM - 3:30 PM CT

• (T1430-09-57) From Miscibility Modeling to Performance: Developing Stable ASD Granules of Nifedipine Using Poloxamer and Copovidone
  Tuesday, November 11, 2025

  2:30 PM - 3:30 PM CT

• (T1530-09-60) Lipid-Based Formulations: How to Predict Rat In Vivo PK Profile with In Vitro + In Silico Approach
  Tuesday, November 11, 2025

  3:30 PM - 4:30 PM CT